No pharmaceutical product may be lawfully imported, distributed, or sold in Iraq without first being registered with the Iraqi Ministry of Health. The registration process is administered primarily by the Iraqi Drug Control Department (IDCD, دائرة سيطرة وبحوث الأدوية), which evaluates each product against quality, safety, and efficacy standards before granting marketing authorization. For both local manufacturers and foreign companies seeking market entry, understanding the legal architecture of this process is essential, not only because registration is a prerequisite to commercial activity, but because the conditions imposed at registration shape the entire commercial life of the product in Iraq.
The principal legal foundation for drug registration in Iraq is the Public Health Law No. 89 of 1981, supplemented by ministerial instructions issued by the Ministry of Health and technical guidelines published by the IDCD. These instructions are updated periodically and govern matters such as the format of the registration file, fees, sample requirements, and the conditions under which a product may be denied, suspended, or withdrawn from the market. Familiarity with the published instructions, and with how the IDCD applies them in practice, is essential for any successful application.
Who May Apply
Eligibility to submit a registration application is restricted. Foreign manufacturers cannot apply directly to the IDCD; they must act through a locally registered scientific office or an authorized Iraqi agent. The scientific office is, in legal terms, the regulatory face of the foreign manufacturer in Iraq, and the Ministry of Health holds it accountable for many of the obligations that follow registration. Scientific offices must themselves hold a valid license from the Ministry, meeting criteria related to premises, qualified pharmacist personnel, and financial guarantees. Local manufacturers, by contrast, apply directly, but only after they have demonstrated that their facilities are operating in compliance with Good Manufacturing Practice.
Registration File
At the heart of the process is the registration file. Iraq has progressively aligned its file format with the international Common Technical Document (CTD) structure, organized into administrative, quality, non-clinical, and clinical modules. While the IDCD does not require the full ICH CTD in every case, a well-prepared filealong CTD lines is typically the most efficient way to satisfy the regulator’s requirements and allows the same file to support applications in multiple jurisdictions.
The core supporting documents that the IDCD expects with most applications include:
- A Certificate of Pharmaceutical Product (CPP) issued by the regulatory authority of the country of origin
- A Free Sale Certificate confirming that the product is lawfully marketed at home
- Valid GMP certification covering the manufacturing site
- A full quality control fileincluding specifications, analytical methods, and stability data
- Bioequivalence studies for generic products
- Product samples and artwork for inner and outer packaging
- Proposed Arabic and English labeling and patient information leaflet
Beyond the content of these documents, the legalization chain attached to them is often what determines whether an application moves forward or stalls. All foreign-language documents must be officially translated into Arabic and legalized through the Iraqi embassy or consulate in the country of origin, followed by authentication by the Iraqi Ministry of Foreign Affairs. In our experience, missing or improperly executed legalization stamps are among the most common reasons applications are returned for correction, sometimes adding months to the timeline.
Review and the “Needs-Based” Approach
Once submitted, the fileis reviewed administratively for completeness before being passed to the technical committees within the IDCD. These committees evaluate manufacturing quality, stability, comparative pricing, therapeutic value, and, most importantly the existence of equivalent products already registered in Iraq. This last factor is distinctive. Iraq operates what is best described as a needs-based registration philosophy: a new product may be refused not only on quality grounds but also where the regulator considers the national market saturated with similar therapeutic alternatives. For commercial planning, this means that the question is not simply whether a product meets technical standards, but also whether the Ministry sees a genuine therapeutic need that the product fills.
The standard statutory timeline is between six and twelve months from the date of a complete submission, though in practice timelines frequently extend beyond this depending on the therapeutic class, the novelty of the product, and the backlog at the technical committees. Priority review may be available for medicines addressing urgent public health needs, including treatments for cancer, rare diseases, or epidemic conditions. Approval, when granted, results in the issuance of a registration certificate valid for five years, with renewal required before expiry.
Obligations After Approval
Registration is not the end of the regulatory relationship, it is the beginning of an ongoing one. Any variation to the product, whether of manufacturing site, formulation, packaging, indication, or labeling, must be notified to or approved by the IDCD depending on its classification as minor or major. Pharmacovigilance obligations begin from the moment the product enters the market, and renewal applications must be planned well in advance of the five-year expiry. Unreported variations, missed renewals, or lapses in pharmacovigilance compliance can all result in suspension of the registration and administrative penalties that may extend to the responsible scientific office as well as the manufacturer.
Challenging a Refusal
Where the IDCD refuses a registration application, the applicant has practical and legal options. The most common first step is to submit additional data addressing the regulator’s concerns and to request reconsideration by the technical committee. Where the refusal is felt to involve procedural or substantive errors, the matter can ultimately be escalated to the Administrative Judiciary, although in practice well-prepared resubmissions resolve most cases before formal litigation is needed. Legal representation can be decisive at this stage, particularly where the refusal involves technical findings that require coordinated regulatory and legal response.
Strategic Considerations
For companies entering the Iraqi pharmaceutical market for the first time, drug registration is the gateway and the most consequential regulatory step. Strategic planning should account not only for the technical preparation of the file and the choice of local partner, but also for the management of legalization logistics, the pricing strategy that will accompany registration, and the long-term obligations that follow approval. Many of the disputes and disappointments we see arise not from a poor product or a hostile regulator, but from underestimation of how interconnected these elements are. With proper preparation, the process is navigable; without it, applications often stall or fail at avoidable junctures.
How We Can Help
Etihad Law Firm regularly advises pharmaceutical manufacturers, importers, and scientific offices on the full registration lifecycle in Iraq, from file preparation and submission through variations, renewals, and disputes before the Ministry of Health and the Iraqi courts. We combine regulatory and litigation experience to support clients at every stage of the process.